For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the emergence of Tafamidis and Attruby represents a true breakthrough . These novel therapies preserve the transthyretin protein, slowing its harmful build-up and alleviating the severity of the condition . Patients are now reporting positive outcome… Read More